{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:24:43Z","timestamp":1764332683226},"reference-count":120,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2019,1,17]]},"abstract":"<jats:sec>\n<jats:title>Background: <\/jats:title>\n<jats:p>Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment\nfor acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barr\u00e9\nSyndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor\nneuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised\ncomplications which are reviewed in this article.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Discussion and Conclusion: <\/jats:title>\n<jats:p>Most adverse events are immediate and mild such as headache, fever and\nnausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed\ncomplications are rare but may be serious, including thromboembolic events and acute kidney injury,\nand these and associated risk factors are also discussed. We emphasise the importance of safe IVIg\nadministration and highlight practical measures to minimise complications of this therapy.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1574886313666181017121139","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T08:09:55Z","timestamp":1539850195000},"page":"3-13","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review"],"prefix":"10.2174","volume":"14","author":[{"given":"Ahmed","family":"Abbas","sequence":"first","affiliation":[{"name":"Department of Neurophysiology, Queen Elizabeth Hospital, University Hospital of Birmingham, Birmingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf A.","family":"Rajabally.","sequence":"additional","affiliation":[{"name":"Department of Neurophysiology, Queen Elizabeth Hospital, University Hospital of Birmingham, Birmingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/15748863113089990040","volume":"8","author":"Jacob S.","year":"2013","unstructured":"Jacob S, Rajabally YA.  Immunomodulation in inflammatory neuropathies: Rationale and safety.","journal-title":"Curr Drug Saf"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1537-2995.2003.00519.x","volume":"43","author":"Knezevic-Maramica I.","year":"2003","unstructured":"Knezevic-Maramica I, Kruskall MS.  Intravenous immune globulins: An update for clinicians.","journal-title":"Transfusion"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mus.21433","volume":"40","author":"Donofrio P.D.","year":"2009","unstructured":"Donofrio PD, Berger A, Brannagan TH.  Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.","journal-title":"Muscle Nerve"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","volume":"13","author":"Lunemann J.D.","year":"2016","unstructured":"Lunemann JD, Quast I, Dalakas MC.  Efficacy of intravenous immunoglobulin in neurological diseases.","journal-title":"Neurotherapeutics"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"388","author":"Willison H.J.","year":"2016","unstructured":"Willison HJ, Jacobs BC, van Doorn PA.  Guillain-Barre syndrome.","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2174\/187152812800959059","volume":"11","author":"Rajabally Y.A.","year":"2012","unstructured":"Rajabally YA.  Treatment of Guillain-Barre syndrome: A review.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref=7","first-page":"CD002063","author":"Hughes R.A.","year":"2014","unstructured":"Hughes RA, Swan AV, van Doorn PA.  Intravenous immunoglobulin for Guillain-Barre syndrome.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","volume":"86","author":"Mathey E.K.","year":"2015","unstructured":"Mathey EK, Park SB, Hughes RA.  Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4103\/1673-5374.165594","volume":"10","author":"Rajabally Y.A.","year":"2015","unstructured":"Rajabally YA.  Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy.","journal-title":"Neural Regen Res"},{"key":"ref=10","first-page":"CD001797","author":"Eftimov F.","year":"2013","unstructured":"Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=11","first-page":"CD010369","volume":"1","author":"Oaklander A.L.","year":"2017","unstructured":"Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH.  Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jns.12176","volume":"21","author":"Adrichem M.E.","year":"2016","unstructured":"Adrichem ME, Eftimov F, van Schaik IN.  Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.","journal-title":"J Peripher Nerv Syst"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","volume":"8","author":"Vlam L.","year":"2011","unstructured":"Vlam L, van der Pol WL, Cats EA.  Multifocal motor neuropathy: Diagnosis, pathogenesis and treatment strategies.","journal-title":"Nat Rev Neurol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"Federico P.","year":"2000","unstructured":"Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE.  Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study.","journal-title":"Neurology"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"Leger J.M.","year":"2001","unstructured":"Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N.  Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study.","journal-title":"Brain"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jns5.12046","volume":"18","author":"Hahn A.F.","year":"2013","unstructured":"Hahn AF, Beydoun SR, Lawson V.  A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.","journal-title":"J Peripher Nerv Syst"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","volume":"7","author":"Jacob S.","year":"2009","unstructured":"Jacob S, Rajabally YA.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.","journal-title":"Curr Neuropharmacol"},{"key":"ref=18","first-page":"1","volume":"22","author":"Dezsi L.","year":"2016","unstructured":"Dezsi L, Horvath Z, Vecsei L.  Intravenous immunoglobulin: Pharmacological properties and use in polyneuropathies.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"Elovaara I.","year":"2008","unstructured":"Elovaara I, Apostolski S, van Doorn P.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.","journal-title":"Eur J Neurol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/CPJ.0b013e3182a78ecf","volume":"3","author":"Ruzhansky K.","year":"2013","unstructured":"Ruzhansky K, Brannagan TH.  Intravenous immunoglobulin for treatment of neuromuscular disease.","journal-title":"Neurol Clin Pract"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","volume":"250","author":"Stangel M.","year":"2003","unstructured":"Stangel M, Kiefer R, Pette M, Smolka MN, Marx P, Gold R.  Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.","journal-title":"J Neurol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000073059","volume":"50","author":"Wittstock M.","year":"2003","unstructured":"Wittstock M, Benecke R, Zettl UK.  Therapy with intravenous immunoglobulins: Complications and side-effects.","journal-title":"Eur Neurol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1517\/14740338.2010.484419","volume":"9","author":"Caress J.B.","year":"2010","unstructured":"Caress JB, Kennedy BL, Eickman KD.  Safety of intravenous immunoglobulin treatment.","journal-title":"Expert Opin Drug Saf"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","volume":"78","author":"Patwa H.S.","year":"2012","unstructured":"Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT.  Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology.","journal-title":"Neurology"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","volume":"122","author":"Bonilla F.A.","year":"2008","unstructured":"Bonilla FA.  Intravenous immunoglobulin: Adverse reactions and management.","journal-title":"J Allergy Clin Immunol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","volume":"27","author":"Stiehm E.R.","year":"2013","unstructured":"Stiehm ER.  Adverse effects of human immunoglobulin therapy.","journal-title":"Transfus Med Rev"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N","volume":"19","author":"Bertorini T.E.","year":"1996","unstructured":"Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH.  Complications of intravenous gammaglobulin in neuromuscular and other diseases.","journal-title":"Muscle Nerve"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.autrev.2015.09.002","volume":"15","author":"Cherin P.","year":"2016","unstructured":"Cherin P, Marie I, Michallet M.  Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.","journal-title":"Autoimmun Rev"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","volume":"21","author":"Nydegger U.E.","year":"1999","unstructured":"Nydegger UE, Sturzenegger M.  Adverse effects of intravenous immunoglobulin therapy.","journal-title":"Drug Saf"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"Orbach H.","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y.  Intravenous immunoglobulin: Adverse effects and safe administration.","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","volume":"32","author":"Abolhassani H.","year":"2012","unstructured":"Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: Systematic review and meta-analysis.","journal-title":"J Clin Immunol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1529-8019.2007.00142.x","volume":"20","author":"Fernandez A.P.","year":"2007","unstructured":"Fernandez AP, Kerdel FA.  The use of i.v. IG therapy in dermatology.","journal-title":"Dermatol Ther"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","volume":"47","author":"Brannagan T.H.","year":"1996","unstructured":"Brannagan TH, Nagle KJ, Lange DJ, Rowland LP.  Complications of intravenous immune globulin treatment in neurologic disease.","journal-title":"Neurology"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"Hughes R.","year":"2001","unstructured":"Hughes R, Bensa S, Willison H.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.","journal-title":"Ann Neurol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archderm.142.2.213","volume":"142","author":"Vecchietti G.","year":"2006","unstructured":"Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE.  Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: Report of 4 cases and review of the literature.","journal-title":"Arch Dermatol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2133.2004.06158.x","volume":"151","author":"Sarmiento E.","year":"2004","unstructured":"Sarmiento E, Micheloud D, Carbone J.  Complement consumption associated with eczematous cutaneous reaction during infusions of high doses of intravenous immunoglobulin.","journal-title":"Br J Dermatol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.57.7.778","volume":"57","author":"Donaghy M.","year":"1994","unstructured":"Donaghy M, Mills KR, Boniface SJ.  Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","volume":"6","author":"Hamrock D.J.","year":"2006","unstructured":"Hamrock DJ.  Adverse events associated with intravenous immunoglobulin therapy.","journal-title":"Int Immunopharmacol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198602273140907","volume":"314","author":"Burks A.W.","year":"1986","unstructured":"Burks AW, Sampson HA, Buckley RH.  Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.","journal-title":"N Engl J Med"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"Lunemann J.D.","year":"2015","unstructured":"Lunemann JD, Nimmerjahn F, Dalakas MC.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.","journal-title":"Nat Rev Neurol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00005-016-0410-1","volume":"65","author":"Williams S.J.","year":"2017","unstructured":"Williams SJ, Gupta S.  Anaphylaxis to IVIG.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","volume":"129","author":"Rachid R.","year":"2012","unstructured":"Rachid R, Bonilla FA.  The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: A comprehensive review of the literature.","journal-title":"J Allergy Clin Immunol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"Perez E.E.","year":"2017","unstructured":"Perez EE, Orange JS, Bonilla F.  Update on the use of immunoglobulin in human disease: A review of evidence.","journal-title":"J Allergy Clin Immunol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/1744666X.2017.1334552","volume":"13","author":"Dhami S.","year":"2017","unstructured":"Dhami S, Sheikh A.  Anaphylaxis: Epidemiology, aetiology and relevance for the clinic.","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1537-2995.2001.41020264.x","volume":"41","author":"Rizk A.","year":"2001","unstructured":"Rizk A, Gorson KC, Kenney L, Weinstein R.  Transfusion-related acute lung injury after the infusion of IVIG.","journal-title":"Transfusion"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.090725","volume":"37","author":"Voulgari P.V.","year":"2010","unstructured":"Voulgari PV, Paschou S, Svarna E, Tsifetaki N, Drosos AA.  Images in rheumatology. Transfusion-related acute lung injury during intravenous immunoglobulin treatment.","journal-title":"J Rheumatol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1423-0410.2012.01645.x","volume":"104","author":"Stoclin A.","year":"2013","unstructured":"Stoclin A, Delbos F, Dauriat G.  Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient.","journal-title":"Vox Sang"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/trf.12731","volume":"54","author":"Quest G.R.","year":"2014","unstructured":"Quest GR, Gaal H, Clarke G, Nahirniak S.  Transfusion-related acute lung injury after transfusion of pooled immune globulin: A case report.","journal-title":"Transfusion"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12028-015-0115-z","volume":"23","author":"Reddy D.R.","year":"2015","unstructured":"Reddy DR, Guru PK, Blessing MM, Stubbs JR, Rabinstein AA, Wijdicks EF.  Transfusion-Related acute lung injury after IVIG for myasthenic crisis.","journal-title":"Neurocrit Care"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/01.CCM.0000214311.56231.23","volume":"34","author":"Gajic O.","year":"2006","unstructured":"Gajic O, Gropper MA, Hubmayr RD.  Pulmonary edema after transfusion: How to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury.","journal-title":"Crit Care Med"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/17512433.2016.1105131","volume":"9","author":"Azizi G.","year":"2016","unstructured":"Azizi G, Abolhassani H, Asgardoon MH.  Managing patients with side effects and adverse events to immunoglobulin therapy.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1537-2995.2003.00466.x","volume":"43","author":"Wallis J.P.","year":"2003","unstructured":"Wallis JP, Lubenko A, Wells AW, Chapman CE.  Single hospital experience of TRALI.","journal-title":"Transfusion"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4037\/ccn2017770","volume":"37","author":"Henneman E.A.","year":"2017","unstructured":"Henneman EA, Andrzejewski C, Gawlinski A, McAfee K, Panaccione T, Dziel K.  Transfusion-Associated circulatory overload: Evidence-based strategies to prevent, identify, and manage a serious adverse event.","journal-title":"Crit Care Nurse"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","volume":"2","author":"Woodruff R.K.","year":"1986","unstructured":"Woodruff RK, Grigg AP, Firkin FC, Smith IL.  Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients.","journal-title":"Lancet"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/vox.12025","volume":"105","author":"Funk M.B.","year":"2013","unstructured":"Funk MB, Gross N, Gross S.  Thromboembolic events associated with immunoglobulin treatment.","journal-title":"Vox Sang"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","volume":"155","author":"Marie I.","year":"2006","unstructured":"Marie I, Maurey G, Herve F, Hellot MF, Levesque H.  Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.","journal-title":"Br J Dermatol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","volume":"256","author":"Caress J.B.","year":"2009","unstructured":"Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS.  Case-control study of thromboembolic events associated with IV immunoglobulin.","journal-title":"J Neurol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","volume":"308","author":"Rajabally Y.A.","year":"2011","unstructured":"Rajabally YA, Kearney DA.  Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study.","journal-title":"J Neurol Sci"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","volume":"133","author":"Ramirez E.","year":"2014","unstructured":"Ramirez E, Romero-Garrido JA, Lopez-Granados E.  Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: Results from a retrospective cohort study.","journal-title":"Thromb Res"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","volume":"44","author":"Dalakas M.C.","year":"1994","unstructured":"Dalakas MC.  High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events.","journal-title":"Neurology"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.24358","volume":"91","author":"Ammann E.M.","year":"2016","unstructured":"Ammann EM, Haskins CB, Fillman KM.  Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs.","journal-title":"Am J Hematol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","volume":"16","author":"Paran D.","year":"2005","unstructured":"Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R.  Venous and arterial thrombosis following administration of intravenous immunoglobulins.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2710.2011.01287.x","volume":"37","author":"Bentley P.","year":"2012","unstructured":"Bentley P, Rosso M, Sadnicka A, Israeli-Korn S, Laffan M, Sharma P.  Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure.","journal-title":"J Clin Pharm Ther"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2133.2008.08700.x","volume":"159","author":"Pollreisz A.","year":"2008","unstructured":"Pollreisz A, Assinger A, Hacker S.  Intravenous immunoglobulins induce CD32-mediated platelet aggregation","journal-title":"Br J Dermatol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000008040","volume":"41","author":"Sztajzel R.","year":"1999","unstructured":"Sztajzel R, Le Floch-Rohr J, Eggimann P.  High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy?","journal-title":"Eur Neurol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","volume":"65","author":"Wolberg A.S.","year":"2000","unstructured":"Wolberg AS, Kon RH, Monroe DM, Hoffman M.  Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.","journal-title":"Am J Hematol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/ajh.24645","volume":"92","author":"Ammann E.M.","year":"2017","unstructured":"Ammann EM, Chrischilles EA.  A reply to Ovanesov","journal-title":"Am J Hematol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1002\/ajh.24644","volume":"92","author":"Ovanesov M.V.","year":"2017","unstructured":"Ovanesov MV, Menis MD, Scott DE.  Association of immune globulin intravenous and thromboembolic adverse events.","journal-title":"Am J Hematol"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/mus.24942","volume":"53","author":"Lozeron P.","year":"2016","unstructured":"Lozeron P, Not A, Theaudin M.  Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.","journal-title":"Muscle Nerve"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-1797.2010.01399.x","volume":"16","author":"Huang L.","year":"2011","unstructured":"Huang L, Kanellis J, Mulley W.  Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection.","journal-title":"Nephrology (Carlton)"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2230.2008.02809.x","volume":"34","author":"Mignogna M.D.","year":"2009","unstructured":"Mignogna MD, Fortuna G, Leuci S, Ruoppo E, Adamo D, Fedele S.  Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: A preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.","journal-title":"Clin Exp Dermatol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.01701105","volume":"1","author":"Vo A.A.","year":"2006","unstructured":"Vo AA, Cam V, Toyoda M.  Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: A single-center experience.","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=73","author":"Barton JC","year":"1987","unstructured":"Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ.  Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin.","journal-title":"Am J Med"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1345\/aph.18305","volume":"33","author":"Haskin J.A.","year":"1999","unstructured":"Haskin JA, Warner DJ, Blank DU.  Acute renal failure after large doses of intravenous immune globulin.","journal-title":"Ann Pharmacother"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/qjmed\/93.11.751","volume":"93","author":"Levy J.B.","year":"2000","unstructured":"Levy JB, Pusey CD.  Nephrotoxicity of intravenous immunoglobulin.","journal-title":"QJM"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1592\/phco.2005.25.6.886","volume":"25","author":"Itkin Y.M.","year":"2005","unstructured":"Itkin YM, Trujillo TC.  Intravenous immunoglobulin-associated acute renal failure: Case series and literature review.","journal-title":"Pharmacotherapy"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"c143","DOI":"10.1159\/000104424","volume":"106","author":"Daphnis E.","year":"2007","unstructured":"Daphnis E, Stylianou K, Alexandrakis M.  Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.","journal-title":"Nephron Clin Pract"},{"key":"ref=78","first-page":"518","volume":"48","author":"","year":"1999","unstructured":".  Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=79","first-page":"4","volume":"28","author":"Fakhouri F.","year":"2007","unstructured":"Fakhouri F.  Intravenous immunoglobulins and acute renal failure: mechanism and prevention.","journal-title":"Rev Med Interne"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5414\/CN106824","volume":"76","author":"Lin R.Y.","year":"2011","unstructured":"Lin RY, Rodriguez-Baez G, Bhargave GA, Lin H.  Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004 - 2009.","journal-title":"Clin Nephrol"},{"key":"ref=81","first-page":"125","volume":"1","author":"Lakshmanadoss U.","year":"2010","unstructured":"Lakshmanadoss U, Balakrishnan E, DiSalle MR.  Sucrose nephropathy following IV immunoglobulin.","journal-title":"J Basic Clin Pharm"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000354893","volume":"38","author":"Dantal J.","year":"2013","unstructured":"Dantal J.  Intravenous immunoglobulins: In-depth review of excipients and acute kidney injury risk.","journal-title":"Am J Nephrol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/j.ajkd.2009.06.013","volume":"55","author":"Welles C.C.","year":"2010","unstructured":"Welles CC, Tambra S, Lafayette RA.  Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion.","journal-title":"Am J Kidney Dis"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/tme.12083","volume":"24","author":"Desborough M.J.","year":"2014","unstructured":"Desborough MJ, Miller J, Thorpe SJ, Murphy MF, Misbah SA.  Intravenous immunoglobulin-induced haemolysis: A case report and review of the literature.","journal-title":"Transfus Med"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/mus.25693","volume":"56","author":"Levine A.A.","year":"2017","unstructured":"Levine AA, Levine TD, Clarke K, Saperstein D.  Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders.","journal-title":"Muscle Nerve"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1546-0096-9-28","volume":"9","author":"Kemmotsu Y.","year":"2011","unstructured":"Kemmotsu Y, Nakayama T, Matsuura H, Saji T.  Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease.","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"Sekul E.A.","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC.  Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors.","journal-title":"Ann Intern Med"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/trf.13200","volume":"55","author":"Bharath V.","year":"2015","unstructured":"Bharath V, Eckert K, Kang M, Chin-Yee IH, Hsia CC.  Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: A retrospective review at a single tertiary care center.","journal-title":"Transfusion"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1568008033340243","volume":"3","author":"Nettis E.","year":"2003","unstructured":"Nettis E, Calogiuri G, Colanardi MC, Ferrannini A, Tursi A.  Drug-induced aseptic meningitis.","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJM199308193290820","volume":"329","author":"Constantinescu C.S.","year":"1993","unstructured":"Constantinescu CS, Chang AP, McCluskey LF.  Recurrent migraine and intravenous immune globulin therapy.","journal-title":"N Engl J Med"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1526-4610.1998.3804317.x","volume":"38","author":"Finkel A.G.","year":"1998","unstructured":"Finkel AG, Howard JF, Mann JD.  Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications.","journal-title":"Headache"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/trf.13886","volume":"56","author":"Berg R.","year":"2016","unstructured":"Berg R, Fuellenhals E.  Aseptic meningitis following therapy with immune globulins: A combination of product features and patient characteristics?","journal-title":"Transfusion"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/trf.13148","volume":"55","author":"Scott D.E.","year":"2015","unstructured":"Scott DE, Epstein JS.  Hemolytic adverse events with immune globulin products: Product factors and patient risks.","journal-title":"Transfusion"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IJCTM.S94329","volume":"4","author":"Mohamed M.","year":"2016","unstructured":"Mohamed M.  Intravenous immunoglobulin-associated hemolysis: Risk factors, challenges, and solutions.","journal-title":"Int J Clin Transfusion Med"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0022-3476(05)81964-X","volume":"120","author":"Comenzo R.L.","year":"1992","unstructured":"Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM.  Immune hemolysis disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.","journal-title":"J Pediatr"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2215\/CJN.04540709","volume":"4","author":"Kahwaji J.","year":"2009","unstructured":"Kahwaji J, Barker E, Pepkowitz S.  Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1111\/trf.13196","volume":"55","author":"Scott D.E.","year":"2015","unstructured":"Scott DE, Epstein JS.  Safeguarding immune globulin recipients against hemolysis: What do we know and where do we go?","journal-title":"Transfusion"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1111\/trf.13198","volume":"55","author":"Berg R.","year":"2015","unstructured":"Berg R, Shebl A, Kimber MC, Abraham M, Schreiber GB.  Hemolytic events associated with intravenous immune globulin therapy: A qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.","journal-title":"Transfusion"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2015.00011","volume":"6","author":"Spath P.J.","year":"2015","unstructured":"Spath PJ, Granata G, La Marra F, Kuijpers TW, Quinti I.  On the dark side of therapies with immunoglobulin concentrates: The adverse events.","journal-title":"Front Immunol"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJM199201233260413","volume":"326","author":"Ben-Chetrit E.","year":"1992","unstructured":"Ben-Chetrit E, Putterman C.  Transient neutropenia induced by intravenous immune globulin.","journal-title":"N Engl J Med"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00002826-200311000-00009","volume":"26","author":"Matsuda M.","year":"2003","unstructured":"Matsuda M, Hosoda W, Sekijima Y.  Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.","journal-title":"Clin Neuropharmacol"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJM199808273390914","volume":"339","author":"Lawn N.","year":"1998","unstructured":"Lawn N, Wijdicks EF, Burritt MF.  Intravenous immune globulin and pseudohyponatremia.","journal-title":"N Engl J Med"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.10325","volume":"73","author":"Steinberger B.A.","year":"2003","unstructured":"Steinberger BA, Ford SM, Coleman TA.  Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia.","journal-title":"Am J Hematol"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00128071-200708050-00004","volume":"8","author":"Mignogna M.D.","year":"2007","unstructured":"Mignogna MD, Fortuna G, Ruoppo E, Adamo D, Leuci S, Fedele S.  Variations in serum hemoglobin, albumin, and electrolytes in patients receiving intravenous immunoglobulin therapy: A real clinical threat?","journal-title":"Am J Clin Dermatol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10157-006-0416-9","volume":"10","author":"Nguyen M.K.","year":"2006","unstructured":"Nguyen MK, Rastogi A, Kurtz I.  True hyponatremia secondary to intravenous immunoglobulin.","journal-title":"Clin Exp Nephrol"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1111\/trf.13116","volume":"55","author":"Winiecki S.","year":"2015","unstructured":"Winiecki S, Baer B, Chege W.  Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin.","journal-title":"Transfusion"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.1080","volume":"67","author":"Steinberger B.","year":"2001","unstructured":"Steinberger B, Coleman TA.  Multiple complications of IVIG therapy in a patient with Guillain-Barre syndrome.","journal-title":"Am J Hematol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000351804","volume":"38","author":"Liamis G.","year":"2013","unstructured":"Liamis G, Liberopoulos E, Barkas F, Elisaf M.  Spurious electrolyte disorders: A diagnostic challenge for clinicians.","journal-title":"Am J Nephrol"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.0b013e31820d8b40","volume":"76","author":"Saifudheen K.","year":"2011","unstructured":"Saifudheen K, Jose J, Gafoor VA, Musthafa M.  Guillain-Barre syndrome and SIADH.","journal-title":"Neurology"},{"key":"ref=110","first-page":"505","volume":"43","author":"","year":"1994","unstructured":".  Prevention. Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","volume":"26","author":"Gardulf A.","year":"2006","unstructured":"Gardulf A, Nicolay U, Asensio O.  Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.","journal-title":"J Clin Immunol"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","volume":"26","author":"Ochs H.D.","year":"2006","unstructured":"Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous Ig GSG.  Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases.","journal-title":"J Clin Immunol"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/bcpt.12428","volume":"117","author":"Markvardsen L.H.","year":"2015","unstructured":"Markvardsen LH, Christiansen I, Andersen H, Jakobsen J.  Headache and nausea after treatment with high-dose subcutaneous versus intravenous immunoglobulin.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=114","first-page":"213","volume":"61","author":"Eijkhout H.W.","year":"2003","unstructured":"Eijkhout HW, van den Broek PJ, van der Meer JW.  Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy.","journal-title":"Neth J Med"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clim.2006.10.002","volume":"122","author":"Horn J.","year":"2007","unstructured":"Horn J, Thon V, Bartonkova D.  Anti-IgA antibodies in common variable immunodeficiency (CVID): Diagnostic workup and therapeutic strategy.","journal-title":"Clin Immunol"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.anai.2018.01.013","volume":"120","author":"Vacchiano V.","year":"2018","unstructured":"Vacchiano V, Liguori R, Pasini E, Avoni P, Donadio V.  Subcutaneous immunoglobulin treatment and thromboembolic risk.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","volume":"112","author":"Berger M.","year":"2004","unstructured":"Berger M.  Subcutaneous immunoglobulin replacement in primary immunodeficiencies.","journal-title":"Clin Immunol"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/mus.25409","volume":"55","author":"Racosta J.M.","year":"2017","unstructured":"Racosta JM, Sposato LA, Kimpinski K.  Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.","journal-title":"Muscle Nerve"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jns.2017.04.039","volume":"378","author":"Markvardsen L.H.","year":"2017","unstructured":"Markvardsen LH, Harbo T.  Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs.","journal-title":"J Neurol Sci"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrneurol.2017.179","volume":"14","author":"Wakerley B.R.","year":"2018","unstructured":"Wakerley BR, Yuki N.  Peripheral neuropathies: Subcutaneous immunoglobulin - the future of CIDP treatment?","journal-title":"Nat Rev Neurol"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/166355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T18:57:37Z","timestamp":1555873057000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/166355\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886313666181017121139","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}